Analyst Price Target is $15.00
This price target is based on 5 analysts offering 12 month price targets for AVEO Pharmaceuticals in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 0.00% upside from the last price of $15.00.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in AVEO Pharmaceuticals. This Hold consensus rating has held steady for over two years.
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.